Efficacy of milciclib (PHA-848125AC), a pan-cyclin d-dependent kinase inhibitor, in two phase II studies with thymic carcinoma (TC) and B3 thymoma (B3T) patients.

8519Background: Thymic carcinoma (TC) and B3 thymoma (B3T) are rare malignant tumors of the thymus. While TC, a highly aggressive and easily metastasizing cancer, has a very poor prognosis, B3T is ...